Bioventus Inc. Class A Common Stock
BVSBioventus Inc. Class A (BVS) is a global leader in orthobiologic solutions dedicated to helping patients recover faster from injuries and surgeries. The company develops and commercializes innovative therapies in areas such as bone healing, joint health, and pain management, with a focus on bone graft substitutes, bioactive solutions, and regenerative products to improve patient outcomes.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 31, 2004 | $0.61 | 2004-03-26 | 2004-03-30 |
| December 31, 2003 | $0.61 | 2003-12-26 | 2003-12-30 |
Dividends Summary
- Consistent Payer: Bioventus Inc. Class A Common Stock has rewarded shareholders with 2 dividend payments over the past 1 years.
- Total Returned Value: Investors who held BVS shares during this period received a total of $1.22 per share in dividend income.
- Latest Payout: The most recent dividend of $0.61/share was paid 7968 days ago, on March 31, 2004.
- Dividend Growth: Since 2003, the dividend payout has grown by 0.0%, from $0.61 to $0.61.
Company News
Bioventus secured a new $400 million credit agreement, replacing its previous 2019 credit facilities, which reduces interest expenses and increases liquidity from $40 million to $100 million in revolving credit.
The global intramedullary nail market is expected to grow rapidly, driven by the rising incidence of bone fractures, particularly among the aging population, and advancements in surgical techniques. However, the market faces challenges such as high procedural costs, the need for skilled professionals, and competition from alternative fixation dev...
The global osteoarthritis therapeutics market is expected to grow from USD 9.91 billion in 2024 to USD 24.34 billion by 2034, driven by the rising prevalence of osteoarthritis and technological advancements in surgical treatments. Europe and Asia Pacific are the key regional markets.
The U.S. osteoarthritis injectables market is expected to grow significantly due to the rising prevalence of osteoarthritis, the growing geriatric population, and increased R&D activities for injectable drug development.
The article discusses how September has historically been a weak month for the stock market, but this year the S&P 500, Dow, and Nasdaq have gained over 1% so far, breaking a 5-year trend. The author recommends buying three breakout stocks that could take advantage of the broader market's upward movement: Bioventus (BVS), Great Lakes Dredge & Doc...
